About Flex Pharma
Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: FLKS
- Previous Close: $4.42
- 50 Day Moving Average: $4.65
- 200 Day Moving Average: $7.49
- 52-Week Range: $3.90 - $13.97
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.46
- P/E Growth: 0.00
- Market Cap: $70.58M
- Outstanding Shares: 16,530,000
- Beta: 3.51
- Return on Equity: -49.80%
- Return on Assets: -47.79%
Companies Related to Flex Pharma:
- Current Ratio: 17.68%
- Quick Ratio: 17.62%
What is Flex Pharma's stock symbol?
Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."
Where is Flex Pharma's stock going? Where will Flex Pharma's stock price be in 2017?
6 brokerages have issued 12 month price targets for Flex Pharma's shares. Their forecasts range from $10.00 to $40.00. On average, they anticipate Flex Pharma's share price to reach $22.80 in the next twelve months.
When will Flex Pharma announce their earnings?
Flex Pharma is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
Who owns Flex Pharma stock?
Flex Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (2.74%), FMR LLC (1.52%), State Street Corp (0.83%) and Royce & Associates LP (0.41%). Company insiders that own Flex Pharma stock include Christoph H Westphal, John P Mccabe, Marc D Kozin, Michelle Stacy, Roderick Mackinnon and Thomas Wessel.
Who bought Flex Pharma stock? Who is buying Flex Pharma stock?
Flex Pharma's stock was purchased by a variety of institutional investors in the last quarter, including Royce & Associates LP and State Street Corp. Company insiders that have bought Flex Pharma stock in the last two years include Christoph H Westphal, John P Mccabe, Marc D Kozin, Michelle Stacy, Roderick Mackinnon and Thomas Wessel.
How do I buy Flex Pharma stock?
Shares of Flex Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Flex Pharma stock cost?
One share of Flex Pharma stock can currently be purchased for approximately $4.27.